A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Clinical Trial Grant
Awarded By
Servier Bio-Innovation, LLC
Start Date
March 14, 2025
End Date
March 20, 2030
Awarded By
Servier Bio-Innovation, LLC
Start Date
March 14, 2025
End Date
March 20, 2030